Lower relapse incidence with haploidentical versus matched sibling or unrelated donor hematopoietic cell transplantation for core-binding factor AML patients in CR2: A study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
Journal
American journal of hematology
ISSN: 1096-8652
Titre abrégé: Am J Hematol
Pays: United States
ID NLM: 7610369
Informations de publication
Date de publication:
24 Apr 2024
24 Apr 2024
Historique:
revised:
26
03
2024
received:
24
01
2024
accepted:
11
04
2024
medline:
24
4
2024
pubmed:
24
4
2024
entrez:
24
4
2024
Statut:
aheadofprint
Résumé
Allogeneic hematopoietic cell transplantation (allo-HCT) is recommended for core-binding factor mutated (CBF) AML patients achieving second complete remission (CR2). However, approximately 20% of patients may relapse after transplant and donor preference remains unclear. We compared in this EBMT global multicenter registry-based analysis the allo-HCT outcomes using either haploidentical (Haplo), matched siblings donors (MSD), or 10/10 matched unrelated donors (MUD). Data from 865 de novo adult CBF AML patients in CR2 receiving allo-HCT in 227 EBMT centers from 2010 to 2022 were analyzed, in which 329 MSD, 374 MUD, and 162 Haplo-HCTs were included. For the entire cohort, 503 (58%) patients were inv(16)/CBFB-MYH11 and 362 patients (42%) were t(8;21)/RUNX1-RUNX1T1 AML. On multivariate analysis, Haplo-HCT was associated with a lower Relapse Incidence (RI) compared to either MSD (hazard ratio [HR] = 0.56, 95% CI 0.32-0.97; p < .05) or MUD (HR = 0.57, 95% CI: 0.33-0.99, p < .05). No significant difference was observed among the 3 types of donors on LFS, OS and GRFS. CBF-AML with t(8;21) was associated with both higher RI (HR = 1.79, 95% CI 1.3-2.47; p < .01) and higher NRM (HR = 1.58, 95% CI 1.1-2.27; p < .01) than CBF-AML with inv(16), which led to worse LFS, OS and GRFS. To conclude, for CBF-AML patients in CR2, Haplo-HCTs were associated with a lower RI compared to MSD and MUD allo-HCTs. There was no difference on LFS, OS or GRFS. CBF AML patients with inv(16) had a better progonosis than those with t(8;21) after allo-HCT in CR2.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : National Natural Science Foundation of China
ID : 82000180
Organisme : Medical Science and Technology Project of Zhejiang Province
ID : 2021KY142
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Al‐Harbi S, Aljurf M, Mohty M, Almohareb F, Ahmed SOA. An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1);RUNX1‐RUNX1T1. Blood Adv. 2020;4(1):229‐238.
Itzykson R, Duployez N, Fasan A, et al. Clonal interference of signaling mutations worsens prognosis in core‐binding factor acute myeloid leukemia. Blood. 2018;132(2):187‐196.
Gorin NC, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem‐cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(19):3183‐3188.
Wang Y, Wu DP, Liu QF, et al. In adults with t(8;21)AML, posttransplant RUNX1/RUNX1T1‐based MRD monitoring, rather than c‐KIT mutations, allows further risk stratification. Blood. 2014;124(12):1880‐1886.
Zhu HH, Zhang XH, Qin YZ, et al. MRD‐directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013;121(20):4056‐4062.
Halaburda K, Labopin M, Mailhol A, et al. Allogeneic stem cell transplantation in second complete remission for core binding factor acute myeloid leukemia: a study from the acute leukemia working Party of the European Society for blood and marrow transplantation. Haematologica. 2020;105(6):1723‐1730.
Sanz J, Galimard JE, Labopin M, et al. Post‐transplant cyclophosphamide after matched sibling, unrelated and haploidentical donor transplants in patients with acute myeloid leukemia: a comparative study of the ALWP EBMT. J Hematol Oncol. 2020;13(1):46.
Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15(12):1628‐1633.
Harris AC, Young R, Devine S, et al. International, multicenter standardization of acute graft‐versus‐host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium. Biol Blood Marrow Transplant. 2016;22(1):4‐10.
Jagasia MH, Greinix HT, Arora M, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: I. The 2014 diagnosis and staging working group report. Biol Blood Marrow Transplant. 2015;21(3):389‐401. e381.
Tazi Y, Arango‐Ossa JE, Zhou Y, et al. Unified classification and risk‐stratification in acute myeloid leukemia. Nat Commun. 2022;13(1):4622.
Schlenk RF, Pasquini MC, Pérez WS, et al. HLA‐identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008;14(2):187‐196.
Luznik L, O'Donnell PV, Symons HJ, et al. HLA‐haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high‐dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641‐650.
Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical‐sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956‐3962.
Yu S, Huang F, Wang Y, et al. Haploidentical transplantation might have superior graft‐versus‐leukemia effect than HLA‐matched sibling transplantation for high‐risk acute myeloid leukemia in first complete remission: a prospective multicentre cohort study. Leukemia. 2020;34(5):1433‐1443.
Darwish C, Farina K, Tremblay D. The core concepts of core binding factor acute myeloid leukemia: current considerations for prognosis and treatment. Blood Rev. 2023;62:101117.
Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a cancer and leukemia group B study. J Clin Oncol. 2005;23(24):5705‐5717.
Saraceni F, Beohou E, Labopin M, et al. Thiotepa, busulfan and fludarabine compared to busulfan and cyclophosphamide as conditioning regimen for allogeneic stem cell transplant from matched siblings and unrelated donors for acute myeloid leukemia. Am J Hematol. 2018;93(10):1211‐1219.
Duléry R, Bastos J, Paviglianiti A, et al. Thiotepa, Busulfan, and Fludarabine conditioning regimen in T cell‐replete HLA‐Haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019;25(7):1407‐1415.
Passweg JR, Labopin M, Christopeit M, et al. Postremission consolidation by autologous hematopoietic cell transplantation (HCT) for acute myeloid leukemia in first complete remission (CR) and negative implications for subsequent allogeneic HCT in second CR: a study by the acute leukemia working Party of the European Society for blood and marrow transplantation (EBMT). Biol Blood Marrow Transplant. 2020;26(4):659‐664.
Christopeit M, Labopin M, Gorin NC, et al. Allogeneic stem cell transplantation following relapse post autologous stem cell transplantation in adult patients with acute myeloid leukemia: a retrospective analysis of 537 patients from the acute leukemia working party of the EBMT. Am J Hematol. 2018;93(12):1532‐1542.
Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140(12):1345‐1377.
Kayser S, Kramer M, Martínez‐Cuadrón D, et al. Characteristics and outcome of patients with core‐binding factor acute myeloid leukemia and FLT3‐ITD: results from an international collaborative study. Haematologica. 2022;107(4):836‐843.
Yin JA, O'Brien MA, Hills RK, Daly SB, Wheatley K, Burnett AK. Minimal residual disease monitoring by quantitative RT‐PCR in core binding factor AML allows risk stratification and predicts relapse: results of the United Kingdom MRC AML‐15 trial. Blood. 2012;120(14):2826‐2835.
Ishikawa Y, Kawashima N, Atsuta Y, et al. Prospective evaluation of prognostic impact of KIT mutations on acute myeloid leukemia with RUNX1‐RUNX1T1 and CBFB‐MYH11. Blood Adv. 2020;4(1):66‐75.
Ragon BK, Daver N, Garcia‐Manero G, et al. Minimal residual disease eradication with epigenetic therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2017;92(9):845‐850.
Senapati J, Shoukier M, Garcia‐Manero G, et al. Activity of decitabine as maintenance therapy in core binding factor acute myeloid leukemia. Am J Hematol. 2022;97(5):574‐582.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in previously untreated acute myeloid leukemia. N Engl J med. 2020;383(7):617‐629.
Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c‐KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463‐3468.
Paschka P, Schlenk RF, Weber D, et al. Adding dasatinib to intensive treatment in core‐binding factor acute myeloid leukemia‐results of the AMLSG 11‐08 trial. Leukemia. 2018;32(7):1621‐1630.
Kong J, Zheng FM, Wang ZD, et al. Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2023;58:777‐783.
Perl AE, Martinelli G, Cortes JE, et al. Gilteritinib or chemotherapy for relapsed or refractory FLT3‐mutated AML. N Engl J med. 2019;381(18):1728‐1740.
Hoffmann AP, Besch AL, Othus M, et al. Early achievement of measurable residual disease (MRD)‐negative complete remission as predictor of outcome after myeloablative allogeneic hematopoietic cell transplantation in acute myeloid leukemia. Bone Marrow Transplant. 2020;55(3):669‐672.
Nagler A, Labopin M, Huang XJ, et al. Non‐T depleted haploidentical stem cell transplantation in AML patients achieving first complete remission after one versus two induction courses: a study from the ALWP/EBMT. Bone Marrow Transplant. 2022;57(4):572‐578.